Toronto Dominion Bank Sells 600 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Posted by on May 11th, 2023

Toronto Dominion Bank trimmed its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 1.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 30,706 shares of the company’s stock after selling 600 shares during the quarter. Toronto Dominion Bank’s holdings in Ionis Pharmaceuticals were worth $1,159,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Duality Advisers LP increased its holdings in Ionis Pharmaceuticals by 824.1% in the 4th quarter. Duality Advisers LP now owns 53,524 shares of the company’s stock worth $2,022,000 after buying an additional 47,732 shares in the last quarter. Bleakley Financial Group LLC bought a new stake in Ionis Pharmaceuticals in the 4th quarter worth about $498,000. New England Capital Financial Advisors LLC bought a new stake in Ionis Pharmaceuticals in the 4th quarter worth about $53,000. Illinois Municipal Retirement Fund bought a new stake in Ionis Pharmaceuticals in the 4th quarter worth about $448,000. Finally, Profund Advisors LLC increased its holdings in Ionis Pharmaceuticals by 2.4% in the 4th quarter. Profund Advisors LLC now owns 15,845 shares of the company’s stock worth $598,000 after buying an additional 368 shares in the last quarter. 87.32% of the stock is currently owned by institutional investors.

Ionis Pharmaceuticals Stock Up 0.4 %

NASDAQ IONS opened at $35.83 on Thursday. The stock’s 50 day moving average is $35.65 and its 200 day moving average is $38.48. The company has a current ratio of 9.81, a quick ratio of 9.72 and a debt-to-equity ratio of 2.42. Ionis Pharmaceuticals, Inc. has a 12 month low of $32.62 and a 12 month high of $48.82. The stock has a market cap of $5.13 billion, a PE ratio of -15.51 and a beta of 0.54.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) last posted its quarterly earnings results on Wednesday, May 3rd. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.13. Ionis Pharmaceuticals had a negative return on equity of 57.58% and a negative net margin of 56.85%. The company had revenue of $131.00 million for the quarter, compared to analysts’ expectations of $126.88 million. During the same period in the previous year, the firm earned ($0.46) EPS. The firm’s revenue was down 7.7% compared to the same quarter last year. Research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IONS. Morgan Stanley lifted their price objective on Ionis Pharmaceuticals from $40.00 to $42.00 and gave the stock an “equal weight” rating in a report on Tuesday, April 11th. Needham & Company LLC reissued a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday, February 23rd. StockNews.com began coverage on Ionis Pharmaceuticals in a research report on Thursday, March 16th. They issued a “hold” rating on the stock. Piper Sandler raised their target price on Ionis Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Thursday, January 19th. Finally, SVB Securities dropped their target price on Ionis Pharmaceuticals from $34.00 to $27.00 in a research report on Thursday, February 23rd. One analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $46.64.

Ionis Pharmaceuticals Company Profile

(Get Rating)

Ionis Pharmaceuticals, Inc engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T.

Read More

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.